STK-002
Autosomal Dominant Optic Atrophy (ADOA)
PreclinicalResearch/Discovery
Key Facts
Indication
Autosomal Dominant Optic Atrophy (ADOA)
Phase
Preclinical
Status
Research/Discovery
Company
About Stoke Therapeutics
Stoke Therapeutics is developing a new category of RNA medicines focused on upregulating protein expression from functional genes to treat severe genetic diseases. The company's lead program, zorevunersen (STK-001), is in Phase 3 for Dravet syndrome, with recent data published in The New England Journal of Medicine demonstrating potential disease modification. Stoke's strategy leverages its proprietary TANGO platform to address haploinsufficiency disorders, a large class of genetic conditions, and expand into other areas of high unmet medical need. Its $1.91B valuation reflects significant investor confidence in this novel therapeutic approach.
View full company profileTherapeutic Areas
Other Autosomal Dominant Optic Atrophy (ADOA) Drugs
| Drug | Company | Phase |
|---|---|---|
| ABO-505 | Abeona Therapeutics | Preclinical |